{"filing":{"accession_number":"0001213900-26-073986","cik":"0001840563","ticker":"ELAB","company_name":"PMGC Holdings Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ea0296527-8k_pmgc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/ea0296527-8k_pmgc.htm"},"events":[{"id":15281,"run_id":13636,"accession_number":"0001213900-26-073986","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses positive Phase III results from an AI-driven drug discovery program with Yuva Biosciences, in which four small-molecule candidates demonstrated statistically significant ANT1 induction in human skeletal muscle cells. This represents a material operational and strategic milestone in the Company's drug development pipeline, supporting advancement to confirmatory testing. While not a traditional earnings release, M\u0026A activity, or governance event, the disclosure of significant preclinical validation results for a lead development program is material to investors' assessment of the Company's pipeline progress and strategic direction.","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":12982,"accession_number":"0001213900-26-073986","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive Phase III results from an AI-driven drug discovery program with Yuva Biosciences, in which four small-molecule candidates demonstrated statistically significant ANT1 induction in human skeletal muscle cells. This represents a material operational and strategic milestone in the Company's drug development pipeline, supporting advancement to confirmatory testing. While not a traditional earnings release, M\u0026A activity, or governance event, the disclosure of significant preclinical validation results for a lead development program is material to investors' assessment of the Company's pipeline progress and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:38:06.547747+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12982,"accession_number":"0001213900-26-073986","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive Phase III results from an AI-driven drug discovery program with Yuva Biosciences, in which four small-molecule candidates demonstrated statistically significant ANT1 induction in human skeletal muscle cells. This represents a material operational and strategic milestone in the Company's drug development pipeline, supporting advancement to confirmatory testing. While not a traditional earnings release, M\u0026A activity, or governance event, the disclosure of significant preclinical validation results for a lead development program is material to investors' assessment of the Company's pipeline progress and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:38:06.547747+00:00","company_name":"PMGC Holdings Inc.","ticker":"ELAB","filing_date":"2026-07-01"}]}